5959-36-4

Usage

Uses

Used in Pharmaceutical Industry:
Butanoic acid, 4-amino-, ethyl ester is used as a chemical intermediate for the synthesis of various pharmaceutical products. Its reactivity and functional groups make it a valuable component in the development of drugs.
Used in Chemical Industry:
Butanoic acid, 4-amino-, ethyl ester is used as a chemical intermediate for the synthesis of various chemical products, such as polymers and dyes. Its versatility in forming chemical bonds and its polarity make it a useful compound in the production of these materials.

Upstream product

• 10137-67-4 ethyl 3-cyanopropionate 
• 94911-63-4 4-(Dibenzylamino)butansaeure-ethylester 
• 6937-16-2 ethyl γ-aminobutyrate hydrochloride 
• 624-85-1 ethyl hypochlorite 
• 56-12-2 4-amino-n-butyric acid 
• 7647-01-0 hydrogenchloride 
• 64-17-5 ethanol 
• 16051-87-9 3-cyanopropanoic acid 

Downstream Products

• 93902-11-5 4-[(2-ethoxycarbonyl-ethyl)-benzoyl-amino]-butyric acid ethyl ester 
• 100076-47-9 2-[3-(3-Ethoxycarbonyl-propyl)-ureido]-benzoic acid methyl ester 
• 135429-03-7 4-[[[2-(4-chlorophenyl)-3H-imidazo[4,5-b]pyridin-3-yl]acetyl]amino]butanoic acid ethyl ester 
• 142260-58-0 N-<2-<5-(3-phenylpropyl)-2-thienyl>acetyl>-4-aminobutyric acid ethyl ester 
• 96445-37-3 4-[4-(2,6-Dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-benzenesulfonylamino]-butyric acid ethyl ester 
• 1212-57-3 ethyl-4-(benzylamino)butanoate 
• 83356-43-8 1-(2-hydroxy-3-phenoxypropyl)pyrrolidin-2-one 
• 92041-50-4 N-(2-Hydroxy-benzyliden)-4-amino-buttersaeure-ethylester 
• 352348-41-5 4-{[3-(4-cyano-phenyl)-3-aza-spiro[5.5]undecane-9-carbonyl]-amino}-butyric acid ethyl ester 
• 223465-82-5 ethyl 4-{[4-(1-benzofuran-2-yl)benzoyl]amino}butanoate 

Relevant academic research and scientific papers

Fluorescence PET (photo-induced electron transfer) sensor for water based on anthracene-amino acid

An anthracene-amino acid system with two carboxyl groups has been designed and synthesized as a new class of fluorescence PET (photo-induced electron transfer) sensor for detection of water in organic solvents. An enhancement in fluorescence is observed with increasing water content in 1,4-dioxane, THF, acetonitrile and ethanol, which is attributable to the suppression of PET by the intramolecular proton transfer of the carboxyl proton to the amino group. The detection limit and quantitation limit are, respectively, 0.1 and 0.3 wt% for 1,4-dioxane, 0.4 and 1.2 wt% for THF, 0.1 and 0.3 wt% for acetonitrile and 0.1 and 0.3 wt% for ethanol.

Modified Conjugated Diene-Based Polymer And Method Of Preparing The Same

The present invention relates to a modifier represented by Formula 1, a method of preparing the same, a modified conjugated diene-based polymer having a high modification ratio which includes a modifier-derived functional group, and a method of preparing the polymer.

Resveratrol amino acid ester derivative and preparation method thereof

The invention discloses a resveratrol amino acid ester derivative and a preparation method thereof, and belongs to the technical field of fine chemical substance synthesis. The structure of the resveratrol amino acid ester derivative is represented by a formula shown in the description. The resveratrol amino acid ester derivative is synthesized from resveratrol, R amino acid, R' alcohol, dichlorosulfoxide and di(p-nitrobenzene) carbonate with 4-dimethylaminopyridine (DMAP) as a catalyst and acetonitrile as a solvent, wherein the R amino acid is one of alpha-alanine, beta-alanine and gamma-aminobutyric acid, and the R' alcohol is one of methanol, ethanol and n-propanol. The technical problem that resveratrol is difficult to preserve is solved, the pharmacological toxicity introduced by a resveratrol substituent group is lowered, and the resveratrol amino acid ester derivative has the pharmaceutical effects of resveratrol and amino acid. It is expected that the above novel compound playsa great role in beauty treatment and production of fatigue-relieving and blood pressure-lowering medicines.

Design, synthesis, and bioactivity evaluation of novel Bcl-2/HDAC dual-target inhibitors for the treatment of multiple myeloma

Multiple myeloma (MM) is the second most common haematological malignancy. Almost all patients with MM eventually relapse, and most recommended treatment protocols for the patients with relapsed refractory MM comprise a combination of drugs with different mechanisms of action. Therefore novel drugs are in urgent need in clinic. Bcl-2 inhibitors and HDAC inhibitors were proved their anti-MM effect in clinic or under clinical trials, and they were further discovered to have synergistic interactions. In this study, a series of Bcl-2/HDAC dual-target inhibitors were designed and synthesized. Among them, compounds 7e–7g showed good inhibitory activities against HDAC6 and high binding affinities to Bcl-2 protein simultaneously. They also displayed good growth inhibitory activities against human MM cell line RPMI-8226, which proved their potential value for the treatment of multiple myeloma.

Design, synthesis, and potent antiepileptic activity with latent nerve rehabilitation of novel γ-aminobutyric acid derivatives

We aimed to design and synthesize novel γ-aminobutyric acid (GABA) derivatives with the combination of aspirin (ASA) of nerve rehabilitative pharmacophores so as to develop multifunctional drugs useful in the treatment of neurological disorders. Twenty-four novel esters and amides of 1a were synthesized, biologically evaluated for antiepileptic activity with the model of 4-aminopyridine (4-AP), and tested for their capacity of penetrating the blood-brain barrier (BBB) with HPLC. The distribution of 8a, ASA freed by 8a, 7c, and ASA freed by 7c within 24 h in brain tissue was measured. The structure-activity relationship (SAR) was established and the data of Computer Aided Drug Design (CADD) showed good results. With ED50 values of, 0.3684-0.5199 mmol/kg, LD50 1.1487-1.3944 mmol/kg, and therapeutic index (TI) 2.65-3.15, compounds 8a, 3b, 4b, 6c, and 7c exhibited better antiepileptic activities in multiples of 0.3 to 2.2 against the control sodium valproate (VPA). Most importantly, 8a and 7c exhibited excellent antiepileptic activities with TI values of, 3.15 and 3.12, respectively.

γ-Amino butyric acid analogs as novel potent GABA-AT inhibitors: Molecular docking, synthesis, and biological evaluation

A new series, of γ-amino butyric acid analogs were designed and synthesized as novel potent GABA-AT inhibitors. A structure-activity relationship study was performed by correlating the effect of different substituents with GABA-AT inhibitory activity of the title compounds. The preliminary bioassays showed that acid hydrazones exhibited excellent inhibitory activities in micromolar (0.07-0.56 μM) range, while Schiff's bases showed variable results. The most potent compound, 4-amino-N'-[(1Z)-1-(2-bromophenyl) ethylidene]butanehydrazide (AHG177) showed inhibitory potency (IC50) of 0.073 μM. Aminobutyrate transaminase is a pyridoxal-P enzyme which follows a bi-bi ping pong mechanism and in pyridoxamine form can readily transaminate only with succinic semialdehyde and 2-oxoglutarate. The results strongly suggest that only the pyridoxal form of the enzyme is capable of reacting with the ligands. Our findings open up the possibility to extend this protocol to different databases in order to find new potential inhibitor for promising targets based on a rational drug design process.

AZAARENE DERIVATIVES

A compound represented by the general formula: wherein X1 represents a nitrogen atom or a group represented by the formula -CR10=; X2 represents a nitrogen atom or a group represented by the formula -CR11=; Y represents an oxygen atom or the like; R1 represents a C1-6 alkoxy group, an optionally substituted C6-10 aryloxy group, a group represented by the formula -NR12aR12b or the like; R2 represents a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like; R3, R4, R5, R6, R7, R8, R10 and R11 each independently represent a hydrogen atom, a halogen atom, an optionally substituted C1-6 alkyl group, or the like; R9 represents a group represented by the formula -NR16aR16b or the like; and R12a, R12b, R16a and R16b each independently represent a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like, a salt thereof, or a hydrate of the foregoing.

Water soluble 3,5-diacetamido-2,4,6-triiodobenzoic acid derivatives

The invention relates to novel water soluble 3,5-diacetamido-2,4,6-triiodobenzoic acid derivatives, the method for making the same and their use as X-ray contrast agents for vasography, urography, myelography, artrography, fistulography and salpingography.